Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors

Ioannis Kaffes, Emory University
Zhihong Chen, Emory University
Frank Szulzewsky, Fred Hutchinson Cancer Research Center
Cameron J. Herting, Emory University
Ben Gabanic, Emory University
Jose E. Velazquez Vega, Emory University
Jose Velazquez Vega, Emory University
Jeffrey M. Shelton, Emory University
Jeffrey Switchenko, Emory University
James L. Ross, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Oncoimmunology
Volume: Volume 8, Number 11
Publisher: Taylor and Francis Inc. | 2019-08-23, Pages e1655360-e1655360
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1080/2162402X.2019.1655360
Permanent URL: https://pid.emory.edu/ark:/25593/vhc5q

Final published version: http://dx.doi.org/10.1080/2162402X.2019.1655360

Copyright information:
© 2019, © 2019 The Author(s). Published by Taylor & Francis.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed August 28, 2023 3:08 AM EDT
Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors

Ioannis Kaffes, Frank Szulzewsky, Zhihong Chen, Cameron J. Herting, Ben Gabanic, José E. Velázquez Vega, Jennifer Shelton, Jeffrey M. Switchenko, James L. Ross, Leon F. McSwain, Jason T. Huse, Bengt Westermark, Sven Neland, Karin Forsberg-Nilsson, Lene Uhrbom, Naga Prathyusha Maturi, Patrick J. Cimino, Eric C. Holland, Helmut Kettenmann, Cameron W. Brennan, Daniel J. Brat, and Dolores Hambardzumyan

*Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; †Department of Cellular Neurosciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; ‡Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; §Discovery and Developmental Therapeutics Program, Winship Cancer Institute, Emory University, Atlanta, GA, USA; ¶Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA; †Department of Biostatistics and Bioinformatics, Winship Cancer Institute, Emory University, Atlanta, GA, USA; ‡Departments of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¶Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; §Department of Pathology, University of Washington, Seattle, WA, USA; ¶Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; †Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

**ABSTRACT**

Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant subgroups to improve our understanding of pathogenetic mechanisms and patient stratification. Concurrently, the role of immune cells in the tumor microenvironment has received increasing attention, especially T cells and tumor-associated macrophages (TAM). The latter are a mixed population of activated brain-resident microglia and infiltrating monocytes/macrophages, both of which express ionized calcium-binding adapter molecule 1 (IBA1). This study investigated differences in immune cell subpopulations among distinct transcriptional subtypes of GBM. Human GBM samples were molecularly characterized and assigned to Proneural, Mesenchymal or Classical subtypes as defined by NanoString nCounter Technology. Subsequently, we performed and analyzed automated immunohistochemical stainings for TAM as well as specific T cell populations. The Mesenchymal subtype of GBM showed the highest presence of TAM, CD8+ T cells, and FOXP3+ T cells, as compared to Proneural and Classical subtypes. High expression levels of the TAM-related gene AIF1, which encodes the TAM-specific protein IBA1, correlated with a worse prognosis in Proneural GBM, but conferred a survival benefit in Mesenchymal tumors. We used our data to construct a mathematical model that could reliably identify Mesenchymal GBM with high sensitivity using a combination of the aforementioned cell-specific IHC markers. In conclusion, we demonstrated that molecularly distinct GBM subtypes are characterized by profound differences in the composition of their immune microenvironment, which could potentially help to identify tumors amenable to immunotherapy.

**Introduction**

Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor in adults. It is characterized by diffuse infiltration of high-grade glioma cells into the brain parenchyma and resistance to standard of care.1-3 Despite treatment regimens consisting of surgical resection, chemotherapy and radiotherapy, patients have median survival times of only 14.6 to 20.9 months.4,5 Thus, a greater understanding of GBM pathogenesis will provide insight for informed treatment strategies.

Previously, comprehensive analyses of gene expression profiles have identified clinically meaningful subgroups to facilitate the study of this heterogeneous disease.6-9 The Cancer Genome Atlas (TCGA) originally proposed four subtypes, referred to as Proneural (PN), Mesenchymal (MES), Classical (CL), and Neural (NL).8 However, following robust gene expression classification, only three subtypes, PN, MES, and CL, are currently recognized, each with its own characteristic genomic alterations.10-12 Although multiple subtypes can co-exist within a single tumor, both at the regional and single-cell level,13 the designated subtypes reflect the dominant transcriptional program of a specific tumor.

In parallel with efforts to define GBM genomics, transcriptomics, and cell signaling within the tumor cell population, other investigations have attempted to more fully characterize...
its diverse cellular composition. GBM is a dynamic ecosystem composed of neoplastic and non-neoplastic cells, which together form the tumor microenvironment and play a significant role in GBM pathogenesis. Particularly, emphasis has been placed on immune system constituents, especially tumor-associated macrophages (TAM). This mixed population of activated brain-resident microglia and infiltrating bone marrow-derived macrophages constitutes up to 45% of cells within GBM and has been shown to engage in reciprocal interactions with neoplastic cells to promote tumor growth and progression. Although these cell types originate from distinct sources – with progenitor cells of microglia migrating into the brain during embryonic brain development, and macrophages derived from peripheral monocytes only infiltrating the brain as a result of tissue injury – they both express ionized calcium-binding adapter molecule 1 (IBA1), a protein involved in membrane ruffling and phagocytosis that is used to visualize both cell types. With the advent of immunotherapeutic strategies for GBM, T cells have also been subject to increasing scrutiny. Previous studies have found increased expression of immune response-related genes in MES GBM, yet its biological relevance remains unclear. The main aim of this study is to investigate whether the PN, MES and CL subtypes of GBM differ with respect to the presence of TAM and distinct T cell subpopulations.

### Materials and methods

#### Tissue samples and pathological appraisal

Human formalin-fixed, paraffin-embedded (FFPE) GBM samples, post-mortem brain specimens, and de-identified clinical information were provided by Emory University, Memorial Sloan Kettering Cancer Center, Uppsala University, and the University of Washington Medical Center following ethical approval by institutional review boards. Pathologists graded and diagnosed the tissue based on the 2007 World Health Organization Classification of Tumors of the Central Nervous System. The 2016 classification had not yet been published at the time work on this project commenced. Both primary and recurrent tumors were used for this study. All tissue samples were anonymized.

#### Gene expression profiling using nanostring nCounter technology

The procedure to identify GBM subtype based on gene expression levels has been described elsewhere in detail. Briefly, RNA was extracted from tumor samples and expression levels were analyzed by NanoString nCounter Technology (NanoString Technologies, Seattle, U.S.A.) using custom-made probes for 152 genes from the original GBM_2 design for the training (32 in total, 27 GBM, and 5 control brains) and test sets (29 GBM in total) (Supplementary Table S1).

#### Immunohistochemistry (IHC)

FFPE specimens were sectioned at five-micrometers and stained on the DISCOVERY XT platform (Ventana Medical Systems, Inc., Tucson, U.S.A.). TAM and microglia were identified using antibodies against IBA1. Antibodies targeting CD3 and CD8 stained the entire T cell population and cytotoxic T cells, respectively. Regulatory T cells were stained by antibodies against forkhead box P3 (FOXP3). Due to the lack of a validated antibody, the CD4+ T cell number was estimated to be the difference between the CD3+ and CD8+ T cell numbers according to published protocol. In six cases, the number of CD8+ T cells exceeded or was identical to the number of CD3+ T cells, so that the CD4+ T cell population was considered to be equal to the FOXP3+ T cell number, since the latter constitutes a subpopulation of CD4+ T cells. The following primary antibodies were used: Anti-IBA1 (1:500, rabbit polyclonal, #019–19741, Wako Pure Chemical Ind., Ltd., Osaka, Japan); anti-human FOXP3, clone 259D (1:100, mouse monoclonal, #320202, BioLegend, San Diego, U.S.A); anti-human CD8, clone C8/144B (1:100, mouse monoclonal, code M7103, Daco, Glostrup, Denmark); anti-human CD3 (1:100, rabbit polyclonal, code A0452, Daco, Glostrup, Denmark).

#### Immunofluorescent staining

Five-micrometer FFPE sections were deparaffinized and rehydrated before antigen retrieval was performed by heating the sections in citrate solution (Vector Shield) at 93°C for 15 min. The sections were then treated with 0.3% Triton in PBS and blocked with 3% normal donkey serum in PBS for 30 min at room temperature. Primary antibodies targeting CD3 (1:100, rabbit polyclonal, code A0452, Daco, Glostrup, Denmark) and CD2 (1:100, mouse monoclonal, code NBP2-32814, Centennial CO, USA) were incubated with the sections for 90 min at room temperature. Secondary antibodies donkey-anti-rabbit-Alexa 488 and donkey-anti-mouse-Alexa 568 (Invitrogen) at a dilution of 1:500 in PBS were applied to the sections for 1h at room temperature. DAPI (Sigma) was used for nuclear counterstaining. Images were acquired on a Leica DM2500 microscope.

#### Image acquisition

The Nanozoomer 2.0HT (Hamamatsu Photonic K.K., Hamamatsu, Japan) whole slide scanner was utilized to digitalize the stained tissue sections. Image analysis was performed using Fiji. Images were captured at 20X magnification, representing an area of 0.3828 mm² and 0.4263 mm², depending upon the screen used for quantification. Owing to the high number of TAM in GBM, it was not possible to consistently identify those cells individually. Therefore, for IBA1, the percentage of stained area per field was analyzed, whereas the number of cells per field was quantified for CD3, CD8 and FOXP3. The total amount of representative images obtained from each tissue section analyzed with Fiji was standardized based on overall tumor area, but so far as possible, at least five images were captured. In order to account for heterogeneity within individual samples, every tissue section was subdivided into different regions. Each region was subsequently attributed a percentage of the total number of images per section on the basis of its relative size. Investigators were blinded as to the subtype of the GBM.
samples during the quantification process. Necrotic and peri-tumor areas were not included. Pixel width of the images was 454 nanometers and final values were standardized to an area of one mm².

**Microglia/macrophage shape analysis**

Four tumors with adjacent non-tumor tissue were stained for IBA1⁺ cells, including microglia in the healthy brain and TAM. Three images were taken in each of the regions of interest, namely the tumor, peri-tumor, and non-tumor areas. The peri-tumor area was defined as a field in which half of the area resembled tumor and the other half resembled non-tumor tissue based on cellular density and composition, as well as macrophage morphology. In each field, the number of primary processes per IBA1⁺ cell was counted and then averaged as a measure of cell activation. Plot profiles displaying changes in staining intensity in four adjacent fields (one non-tumor, one peri-tumor, and two tumor) were generated for each of the four samples using Fiji. The mean and standard deviation of the relative intensity were plotted with MatLab software (The MathWorks, Inc., Natick, U.S.A).

**TCGA analysis**

Expression levels and survival data corresponding to the genes of interest were obtained from the cbioPortal for Cancer Genomics (Cancer Study: Glioblastoma Multiforme (TCGA, Provisional), Genomic Profiles: mRNA Expression z-Scores (microarray)) in August of 2016, which provides tools for the analysis and visualization of TCGA datasets. All primary GBM with complete gene expression and subtype information were analyzed. In total, 357 samples were included, of which 69 were PN, 106 MES, and 101 CL. Of the remaining samples, 55 demonstrated a NL signature and 26 displayed a glioma-CpG island methylator phenotype (G-CIMP). For the subtype-specific analyses, G-CIMP-positive and NL tumors were excluded. The GBM subtype classification was described by Verhaak et al.

**Mathematical prediction model of GBM subtypes**

The markers IBA1, CD3, FOXP3 and CD8 were combined to create an empirically-derived, threshold-based GBM subtype prediction model. Given the three-level outcome with three possible GBM subtypes, a multinomial model, which is an extension of a logistic regression model with more than two outcomes, was fit for the training set of 29 samples. A set of two independent binary regressions were fit, using the subtype PN as the reference. Parameter estimates were found by solving for three equations: the two binary regression equations (below) and the equation: P(CL) + P(MES) + P(PN) = 1, where P(CL) is the probability of Classical subtype, P(MES) is the probability of Mesenchymal subtype, and P(PN) is the probability of Proneural subtype. Using a test set of 21 samples and the parameter estimates from the multinomial model, predicted probabilities for each subtype were generated for each sample. The subtype with the highest predicted probability for a given sample was considered as the predicted subtype for that sample. For example, if a sample’s set of predicted probabilities was P(CL) = 0.65, P(MES) = 0.2, P(PN) = 0.15, then that sample was classified as a CL subtype based on the model. The sensitivity and specificity for each subtype, along with 95% confidence intervals, were reported (Supplementary Tables S3, S4). P-values from the multinomial model were also reported.

Equations: Set of binary regression equations estimated from the multinomial model:

\[
\log \left( \frac{P(CL)}{P(PN)} \right) = -0.7722 + 0.0350 \times IBA1 - 0.0067 \times FOXP3 + 0.0161 \times CD3 - 0.0040 \times CD8 \\
\log \left( \frac{P(MES)}{P(PN)} \right) = -8.8873 + 0.5496 \times IBA1 + 0.2417 \times FOXP3 + 0.0311 \times CD3 - 0.0594 \times CD8
\]

**Statistical analysis**

Graphs were created with GraphPad Prism 6.0b and 7.04 (GraphPad Software Inc., La Jolla, U.S.A). One-way ANOVA and Tukey’s multiple comparisons tests were used to compare more than two groups. Analyses involving low sample numbers were performed using Dunn’s multiple comparisons test and a two-tailed Mann-Whitney U test. Correlations were analyzed with the Pearson correlation coefficient (r). The Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test were performed for survival analyses. Significance levels were indicated as follows: ns (not significant); * (P < .05); ** (P < .01); *** (P < .001); **** (P < .0001). Details pertaining to individual graphs are included in the figure legends.

**Results**

**Human gene expression data reveal differential immune profiles among GBM subtypes and indicate distinct effects on survival**

Gene expression data corresponding to the immune cell markers of interest were obtained from TCGA and surveyed for differences among the established GBM subtypes PN, MES and CL (Figure 1). Genes analyzed were AIF1 (encoding IBA1), CD8B (beta-chain of CD8), CD4 (CD4), FOXP3 (FOXP3), and CD3G (gamma chain of CD3). We identified a significant upregulation of the macrophage marker AIF1, CD3G and CD4 in MES GBM. To further evaluate the correlative biological significance of increased immune cells in MES tumors, levels for each marker were split into groups of high and low expression in order to identify differences in overall survival.

In PN GBM, AIF1 was the only gene to have an impact on survival. High AIF1 levels were associated with a significantly worse prognosis in patients with PN tumors compared to those PN GBM with low expression (median survival high AIF1: 7.80 months, low AIF1: 10.56 months) (Supplementary Fig. S1). Conversely, in MES GBM, high expression of AIF1 conferred a survival benefit, with median survival lengths in the high-AIF1 cohort being almost twice as long (high AIF1: 14.36 months, low
AIF1: 7.31 months (Figure 2(a)). In the MES subtype, high expression of the T cell marker CD3G was also prognostically beneficial (median survival high CD3G: 14.36 months, low CD3G: 10.43 months) (Supplementary Fig. S2). No significant survival differences were observed in CL tumors (Supplementary Fig. S3).

When all GBM, including those classified as NL and G-CIMP-positive, were combined, high expression levels of FOXP3 and CD3G were associated with improved overall survival (Supplementary Fig. S4).

**GBM is characterized by an increased presence of immune cells compared to naïve control brains**

In order to characterize immune infiltration patterns at the protein level, 56 GBM samples were stained for IBA1, CD8, FOXP3 and CD3. Their averages were compared to those of five control brain samples (Supplementary Fig. S5). Quantification of the IBA1-positive area revealed a significantly increased density of IBA1+ cells in tumor sections compared to naïve brains (mean area of all GBM samples: 13.9%, Controls: 3.9%). Similarly, GBM was characterized by higher numbers of CD8+ (20.3 cells/mm²) and FOXP3+ (3.1 cells/mm²) T cells compared to controls (2.2 and 0.25 cells/mm²). The pan-T cell marker CD3 was also expressed significantly higher in tumor samples (GBM: 44.6 cells/mm², Controls: 1.3 cells/mm²). The slightly lower number of CD3+ T cells in the naïve brains compared to the CD8+ T cell infiltration can be explained by the extremely low levels T cell infiltrates in healthy brains, which is likely below our methods’ threshold of accurate quantification.

**TAM are present at high levels in MES GBM**

Using limited group sizes and differing methodologies to determine the tumor subtype, previous studies have proposed that the number of IBA1+ cells is significantly higher in MES tumors compared to the other subtypes. In order to discriminate between PN, CL, and MES and to increase the...
sample size per subtype, we subsequently compared the density of TAM among the three subgroups at the protein level by IHC. Using NanoString nCounter Technology, we found that, out of the 56 cases of GBM, 13 were characterized as PN, 18 were assigned to the MES subtype, and 19 showed a CL profile. Six tumors classified as G-CIMP-positive were excluded from this analysis. Quantification in Fiji demonstrated that MES GBM showed significantly higher levels of TAM infiltration compared to PN and CL tumors (Figure 2b, c), thus corroborating the TCGA expression data. The results for individual GBM samples and clinical information can be found in Supplementary Table S2.

**The MES subtype of GBM is characterized by increased T cell levels**

A similar infiltration pattern was observed for different T cell populations (Figure 3; Supplementary Fig. S6). CD3 stains all T cell populations and thus showed the highest numbers of all T cell markers, with the PN and CL subtypes not differing significantly (PN: 20.2 cells/mm², CL: 39 cells/mm²) and MES tumors showing markedly increased levels compared to both (76.1 cells/mm²), confirming our observations from TCGA.

CD4⁺, CD8⁺, and FOXP3⁺ T cells (FOXP3⁺ cells consist of both CD8⁺/FOXP3⁺ and CD4⁺/FOXP3⁺) were also found at higher densities in tumors with a MES profile as compared to PN and CL samples. The difference in CD8⁺ T cell infiltration between MES and CL GBM, however, was not significant (P = .08). CD4⁺ T cells were the most common (PN: 11.3 cells/mm², MES: 43.2 cells/mm²), followed by CD8⁺ (PN: 9.4 cells/mm², MES: 32.9 cells/mm²) and FOXP3⁺ T cells (PN: 0.7 cells/mm², MES: 6.3 cells/mm²). Furthermore, significant positive correlations were found between IBA1⁺ TAM and all T cell populations (Supplementary Fig. S7). Figure 4 illustrates the differential immune cell infiltration in each of the GBM subtypes.

Finally, we examined differences in immune cell profiles between the six G-CIMP-positive and all non-G-CIMP tumors. In G-CIMP-positive tumors, we observed a decreased number of CD3⁺ T cells (G-CIMP: 9.5 cells/mm², non-G-CIMP: 20.2 cells/mm²) and CD4⁺ T cells (G-CIMP: 9.5 cells/mm², non-G-CIMP: 26.7 cells/mm²). No differences were seen in the infiltration of other cell types (Supplementary Fig. S8).

**Specific combinations of IHC markers can be utilized to predict MES GBM**

In order to determine the predictive nature of the immune phenotype for each transcriptional subtype, we then investigated the possibility of using a combination of the markers IBA1, CD3, CD8, and FOXP3 to predict the subgroup of our samples. The number

---

**Figure 3.** T cells preferentially infiltrate MES GBM. (a) Representative images depicting infiltrated CD3⁺, FOXP3⁺, and CD8⁺ T cells (arrows) in different GBM subtypes. Scale bars indicate a length of 100 micrometers and 50 micrometers (inserted images). (b) Quantification of the number of CD3⁺ T cells reveals a higher density in MES GBM, with CD3 staining all T cells. (c) Infiltration of CD8⁺ T cells differs significantly between the PN and MES subtypes. CD8⁺ T cell numbers were also higher in MES than CL tumors, but not significantly (p = .08). (d, e) Dot plots demonstrating FOXP3⁺ and CD4⁺ T cells appear in significantly higher numbers in MES GBM. PN and CL GBM show similar levels of infiltration. The average of each tumor is represented by one data point.
of CD4$^+$ cells was estimated by subtracting the number of CD8$^+$ cells from CD3$^+$ cells in accordance with a published protocol\textsuperscript{35} and was therefore not included. Applying our multinomial model to a training set consisting of 9 PN, 9 CL, and 11 MES samples, we found that 18 of the 29 (62.1\%) samples were classified correctly. MES samples were accurately predicted with a sensitivity of 90.9\% (Supplementary Table S3). The training set had less success with the PN and CL subtypes (sensitivity of 55.5\% and 33.3\%, respectively).

The test set was composed of 4 PN, 10 CL, and 7 MES tumors. Of the 21 samples, 13 were classified correctly based on the model (61.9\%). The model accurately predicted the majority of PN and MES samples (sensitivity PN: 100\%, MES: 71.4\%). CL tumors were successfully identified with a sensitivity of only 40\% (Supplementary Table S4). All estimated specificity values were adequate. None of the biomarkers alone were significantly associated with subtype (\(P > .05\), Supplementary Table S5). These results highlight the potential of this IHC-based model to predict GBM subtypes, but necessitate additional studies with larger sample sizes.

**Discussion**

The present study provides evidence of marked differences in the cellular immune profile amongst distinct GBM subtypes. First, we analyzed TCGA gene expression data and found an upregulation of \textit{AIF1}, \textit{CD3G}, and \textit{CD4}, markers of TAM, T-cells, and T-helper cells respectively, in the MES subgroup. Our results reflect those found by Doucette et al., who identified an enrichment of both proinflammatory and immunosuppressive genes in the MES subtype compared to the PN and CL groups by leveraging TCGA data.\textsuperscript{29} It should be noted that not all chains of CD3 are specific T cell markers, with natural killer (NK) cells, for instance, being able to express some CD3 subunits as well.\textsuperscript{47}

Due to limitations associated with the use of high-throughput sequencing techniques, we complemented our initial findings with an immunohistochemical study of immune cell infiltration, which identified increased levels of TAM and T cells in MES GBM. An investigation of human adult and pediatric astrocytomas by Engler et al. also demonstrated higher numbers of TAM in MES GBM compared to tumor area (1.6 primary processes/cell), while the lowest numbers were noted within tumor tissue, with an average of 1.1 per cell (Figure 5(b)). The qualitative perception that the degree of IBA1-positivity gradually increased when going from normal brain to peritumoral brain to brain tumor was confirmed by quantitation of IBA1-positive areas (non-tumor: 5.9\%, peri-tumor: 8.7\%, tumor: 19.9\%) (Figure 5(c)). These phenomena, indicating an increased activation and infiltration of TAM in the tumor compared to the adjacent brain, was further visualized by plot profiles of the changing staining intensity in those regions (Figure 5(d)).

Finally, the percentage of IBA1-positive area in the adjacent brain tissue of eleven tumor samples was compared to that of the five control brain samples in order to examine possible differences in activation (Figure 5(e)). The difference in their means, however, was not significant (naïve control brains: 3.9\%, non-tumor tissue of GBM samples: 4.5\%).
non-MES tumors, albeit using unequal group sizes and without distinguishing among the remaining groups, rendering a definitive assessment difficult. In another study of human PN and MES tumors, Beier et al. similarly showed that TAM and CD8+ T cells preferentially infiltrate MES tumors, although low sample numbers were used and the subtype was determined based on a combination of immunohistochemical markers, preventing a conclusive judgment to be made. Although the same caveats apply to the findings of Sørensen et al, who also demonstrated higher numbers of TAM in MES GBM, our own results combined with the cited studies make a compelling case for a significantly increased presence of TAM infiltration in MES tumors at the protein level. However, using gene expression data, we demonstrated opposite effects of AIF1 in PN and MES GBM, with high expression levels of this marker of TAM leading to a worse prognosis within the former subtype and conferring a survival benefit in the latter, suggesting that high numbers of TAM are not a predictor for patient survival when various subtypes are compared.

With regard to T cell infiltration, the results from previous publications are less conclusive. While Prins et al. demonstrated increased levels of CD3+ and CD8+ cells in MES versus PN tumors in a Phase I trial testing a dendritic cell vaccine, no difference was found in the infiltration of CD4+ and CD8+ cells in a study by Han et al. Both studies, however, applied different molecular classifications, with the former referring to the subtypes proposed by Phillips et al. and the latter grouping their samples according to the systematization put forth by Verhaak et al. Leveraging robust group sizes and focusing on the three subgroups for which strong molecular underpinnings exist, the PN, MES and CL subtypes, we aimed to add clarity to the question of T cell infiltration and demonstrated increased numbers of different T cell

Figure 5. Tumor-associated macrophages (TAM) exhibit distinct morphologies in tumor and non-tumor regions. (a) Image of a GBM section with adjacent brain tissue stained with IBA1. The black rectangles represent images captured to quantify differences in the morphology of TAM in non-tumor (left), peri-tumor (mid), and tumor (right) areas, as well as changes in IBA1-positivity. Peri-tumor areas were defined as a field in which half of the area is non-tumor and the other half is tumor tissue based on macrophage morphology and cellular density. Scale bar corresponds to a length of 10 millimeters. (b) The number of primary processes per IBA1+ cell, a marker for macrophage shape and activation, changes incrementally from non-tumor to tumor areas. The data points represent average numbers of processes per cell in each area of different tumors. (c) Quantification shows the percentage area covered by IBA1+ TAM gradually increases from non-tumor to tumor areas, with each dot representing the average of one sample. Dunn’s multiple comparisons test was performed. (d) Plot profile demonstrating a gradual increase in relative IBA1 immunopositivity with increasing proximity to the tumor parenchyma. The solid dark blue line indicates mean intensity and the shades represent ± one standard deviation (n = 4 independent samples). Examples of TAM highlight their morphological plasticity. The section below the plot profile exemplifies the areas used for this analysis. Staining intensity increases from left (non-tumor) to right (tumor). The scale bar indicates a length of 100 micrometers. (e) Quantification of the percentage of the IBA1-positive area in control brains and non-tumor areas adjacent to GBM indicated no significant difference. Dots represent averages of each sample. Mann-Whitney U test was performed.
populations in MES GBM. Nonetheless, limitations apply to our indirect quantification of CD4+ T cell-infiltration by subtracting CD8+ from CD3+ T cells, as this reduces accuracy in samples that have very low to nearly zero infiltration of T cells, and because a small number of CD3+ cells lack both CD8 and CD4. In a study by Waziri et al. analyzing subsets of CD3+CD56+ infiltrating T cells in GBM, which constituted nearly half of all CD3+ T cells in that sample, CD4/CD8 double-negative T cells only accounted for less than 5% of all CD3+CD56+ cells. 

Despite challenges associated with the use of gene expression profiling studies, the plethora of previous evidence, in addition to our own data, indicate a fundamentally distinct immune profile in MES tumors. These results confirm the findings of Wang et al., who similarly identified an increased immune infiltration in MES GBM in an analysis using CIBERSORT in silico cytometry, which is a computational approach to studying relative cell compositions of tissues. They further demonstrated that tumors switching their monocytic subtype upon recurrence also change their immune profile accordingly, which indicates the inclusion of recurrent tumors in our study may not constitute a confounding variable.

Although the role of TAM in glioma pathogenesis is well-established, the individual effects of the two populations subsumed under this term, microglia- and monocyte-derived macrophages, remain contentious areas of investigation. While some authors have reported microglia constitute the majority of mononuclear cells in GBM, our data using transgenic knock-in reporter mice indicate a clear predominance of monocyte-derived macrophages in PN tumors. 

Unpublished findings from our laboratory indicate that microglia are predominant in MES GBM. Although in mouse systems microglia and monocyte-derived macrophages can be distinguished by using cell type-specific reporter mice, this is not possible in human FFPE tumors specimens due to the lack of cell type-specific IHC markers. Although a recent study using GBM single-cell RNA sequencing proposed unique genes to discriminate microglia from macrophages, validation at the protein level was performed only on two tumor samples by FACS. An improved understanding of the ratio of these cell types might offer clues regarding their differential interactions with neoplastic cells and help explain the survival differences seen in our TCGA analysis.

The prognostic value of infiltrating T cells in GBM is equally controversial. While some studies indicate high CD3+ and CD8+ T cell numbers are associated with prolonged survival, others, such as Zhai et al. in their analysis of the role of the immunosuppressive enzyme IDO1 in gliomas, found high levels of these subpopulations as well as CD4 + T cells to confer an unfavorable outcome. Several investigations have been dedicated to understanding the impact of regulatory T cells on the survival of GBM patients, with the majority not reporting any significant relationship. However, our own finding based on TCGA demonstrating a survival advantage for patients with higher FOXP3 levels, possibly indicating increased Treg cell infiltration, as well as studies implicating high FOXP3+ T cell levels in poorer overall survival, highlight the need for further investigations, especially taking into account the heterogeneity of the Treg cell population. Although controversy exists in the literature regarding FOXP3 being expressed either by macrophages or cancer cells, our results, together with published literature, suggest that its expression is largely limited to CD4+ and CD8+ T cells. In this context, our findings in a small cohort indicating lower CD3+ and CD4+ T cell levels in G-CIMP-positive GBM, which are associated with mutations in isocitrate dehydrogenase 1 (IDH1) and improved survival, further demonstrate the complexity of T cell involvement. This last finding echoes results by Amankulor et al., who identified lower levels of macrophages, T and B cells in a small group of IDH1-mutated grade 2 and 3 gliomas, which, the authors speculate, could potentially contribute to the favorable outcome seen in G-CIMP tumors.

The advent of immune-based therapies for GBM has rendered these questions increasingly pertinent. In their Phase I trial of lystae-pulsed dendritic cells in the treatment of GBM, Prins et al. identified a survival advantage for MES tumors. Interestingly, leveraging their high-throughput approach, Wang et al. demonstrated an increased enrichment of genes related to dendritic cells in the CL subtype, indicating these tumors might benefit from the vaccine. Although the trial was not designed to assess efficacy, it provides a rationale for continued investigations into the role of the immune system in the context of molecular and cellular heterogeneity. The success of immune checkpoint inhibitors in other cancer types such as melanoma or lung cancer has generated interest in these agents as a possible treatment option for GBM patients. Expression of Programmed Death-Ligand 1 (PD-L1) has been shown to be increased in tumors with a MES profile. Worse outcomes have been observed in a correlative study in tumors with higher PD-L1 expression, however a similar previous investigation had not detected a difference in survival. Preclinical studies have demonstrated significant survival advantages in mice treated with inhibitors of PD-1 or PD-L1. Clinical trials, however, have thus far delivered mixed results. Consequently, additional investigations, which take into account the immune heterogeneity laid out in this study, seem warranted.

All of these findings demonstrate the potential of stratification for GBM patients, creating the necessity to translate the subtypes into clinical applications. Molecular characterization, however, is still costly and dependent upon the existence of appropriate facilities. Therefore, we propose a model based on distinct immune cell infiltration patterns that is able to identify MES tumors with a high sensitivity. However, it should be noted, owing to the relatively small sample size used to establish the model, further validation is required. Since the study used archived clinical FFPE specimens, there is significant potential for developing the model to increase the sensitivity of prediction, with the ultimate goal of creating a prognostic model.

In conclusion, our results lend credence to the notion of utterly distinct microenvironments of molecularly heterogeneous GBM subtypes and form the basis for future mechanistic studies investigating their relevance in the context of novel therapeutic strategies and GBM pathogenesis.

Acknowledgments
The authors would like to thank Dr. Suresh Mohla for the inspiration to initiate the project and his active involvement during the entire
process. We would also like to thank the Tumor Microenvironment Network at the National Cancer Institute for providing antibodies for this study. Furthermore, the authors extend their thanks to Neil Anthony for his advice on image quantification, Victor Maximov for fruitful discussions, and Kristina Alikhanyan for technical assistance. The graphic illustrations of immune cells were created by Dave Schumick. This research project was supported in part by the Emory University Integrated Cellular Imaging Microscopy Core of the Emory +Children’s Pediatric Research Center. Moreover, research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions
Planning of the study: DH, IK, HK. Method development: IK, ZC. Provision of samples and clinical information and gene expression profiling: FS, CB, JV, JS, JH, BW, SN, KF, LU, NM, EH, DB. Immunohistochemistry staining: FS. TCGA analysis: IK, DH. Image analysis: IK, CH, JR, LM. Statistical analysis: IK, JMS, ZC. Prediction model: JS, IK, DH. Drafting of the manuscript: IK, DH. All authors read, reviewed, and approved the final manuscript.

Funding
The study was financially supported by funds from National Institutes of Health [R01CA176659]; Swedish Cancer Society [110363]; Swedish Cancer Society [140385]; Swedish Cancer Society [130500]; Swedish Research Council [521-2013-3356]; Berlin Institute of Health; German Research Foundation [DFG SZ 350/1-1]; German Academic Exchange Service; National Institutes of Health (US) [R01NS100864]; National Institutes of Health (US) [F31NS106887]; National Institutes of Health (US) [F31CA232531]; National Institutes of Health (US) [U01CA160882]; National Institutes of Health (US) [AT32GM008620-2].

Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability statement
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

ORCID
Zhihong Chen http://orcid.org/0000-0001-7403-7015
Dolores Hambardzumyan http://orcid.org/0000-0003-1975-4665

References
1. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2012;8:2725–2734.
2. Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D, von Deimling A. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69(4):523–526. doi:10.1001/archneurol.2011.2910.
3. Shu HK, Kim MM, Chen P, Furman F, Julin CM, Israel MA. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A. 1998;95(24):14453–14458. doi:10.1073/pnas.95.24.14453.
4. Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJF, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330.
5. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte F, Toms S, Idhaaib A, Akuwulua MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Jama. 2017;318(23):2306–2316. doi:10.1001/jama.2017.18718.
6. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E, Creighton C. Glioblastoma subclases can be defined by activity among signal pathways and associated genomic alterations. PLoS One. 2009;4(11):e7752. doi:10.1371/journal.pone.0007752.
7. Mischel P5, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liao LM, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003;22(15):2361–2373. doi:10.1038/sj.onc.1206344.
8. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NFI. Cancer Cell. 2010;17(1):98–110. doi:10.1016/j.ccr.2009.12.020.
9. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Sorocoeau L, et al. Molecular subclases of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–173. doi:10.1016/j.ccr.2006.02.019.
10. Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, Yun J, Samanamud J, Sims JS, Banu M, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A. 2014;111(34):12550–12555. doi:10.1073/pnas.1405839111.
11. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al. Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.e6. doi:10.1016/j.ccell.2017.06.003.
12. Sturm D, Witt H, Hovestadt V, Khluong-Quang D-A, Jones DTW, Konermann C, Piffa E, Tönejes M, Sil M, Bender S, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437. doi:10.1016/j.ccr.2012.08.024.
13. Patel AP, Tirosch I, Trombetta JJ, Shalek AK, Gillespie SM, Wakhimoto H, Cahiil DP, Nahed BV, Curry WT, Martuza RL, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, NY). 2014;344(6190):1396–1401. doi:10.1126/science.1254257.
14. Hambardzumyan D, Bergers G. Glioblastoma: defining tumor niches. Trends Cancer. 2015;1(4):252–265. doi:10.1016/j.trecan.2015.10.009.
15. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioneuronal and progression. Nat Neurosci. 2016;19(1):20–27. doi:10.1038/nn.4185.
16. Feng X, Szulzewsky F, Yayovenian A, Chen Z, Heintzmann D, Rasmussen RD, Alvarez-Garcia V, Kim Y, Wang B, Tamagno I, et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncarget. 2015;6(17):15077–15094. doi:10.18632/oncarget.3730.
17. Hu F, A Dzaye OD, Hahn A, Yu Y, Scavetta RJ, Dittmar G, Kaczmarek AK, Dunning KR, Ricciardelli C, Rinnenthal JL, et al. Glioma-derived versican promotes tumor expansion via...
glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro-oncology. 2015;17(2):200–210. doi:10.1093/neuonc/nou324.

18. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: State of the Macrophage. Content of Human Brain Tumors. J Neurosurg. 1979;50:305–311.

19. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol. 1987;74:269–277.

20. Chen Z, Hambardzumyan D. Immune microenvironment in glioblastoma subtypes. Front Immunol. 2018;9:1004. doi:10.3389/fimmu.2018.01004.

21. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Golkan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (New York, NY). 2010;330(6005):841–845. doi:10.1126/science.1194637.

22. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nature Rev Immunol. 2011;11(11):762–774. doi:10.1038/nri31070.

23. Schluesener HJ, Seid K, Kretzschmar J, Meyermann R. Allograft-inflammatory factor-1 in rat experimental autoimmune encephalomyelitis, neuritis, and uveitis expression by activated macrophages and microglial cells. Glia. 1998;24:244–251.

24. Okano T, Nakagawa T, Kita T, Kada S, Yoshimoto M, Nakahata T, Ito J. Bone marrow-derived cells expressing Iba1 are constitutively present as resident tissue macrophages in the mouse cochlea. J Neurosci Res. 2008;86(8):1758–1767. doi:10.1002/jnr.21625.

25. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S. Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci. 2000;113:3073–3084.

26. Prins RM, Soto H, Konkankit V, Odesa SK, Aschenbrenner I, Zhou X, Li Y, et al. Tumor evolution of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–122. doi:10.1158/2326-066X.CIR-13-0028.

27. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpone C, deCarvalho AC, Liu S, Li P, Li Y, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.e6. doi:10.1016/j.ccel.2017.06.003.

28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4.

29. Karstenhuber ER, Huse JT, Berman SH, Pedraza A, Zhang J, Suehara Y, Viale A, Cavatore M, Heguy A, Szerlip N, et al. Involvement of Iba1 in membrane ruffling and phagocytosis of microglia/macrophages. Science (New York, NY). 2010;329(5996):1363. doi:10.1126/science.1194637.

30. Benziman M, Cai H, Lippert SA, Lee J, Draper J, Sui Y, Zhang J, Konno T, Mackay IR, Saldanha JS, et al. Allograft inflammatory factor-1 in rat experimental autoimmune encephalomyelitis, neuritis, and uveitis: expression by activated macrophages and microglial cells. Glia. 1998;24:244–251.

31. Lanier LL, Chang C, Spits H, Phillips JH. Expression of cytotoxic T lymphocyte-associated antigen 4 on human CD4(+) and CD8(+) lymphocytes. J Immunol (Baltimore, Md: 1950). 1987;138(4):1363. doi:10.1111/j.1471-5482.1987.tb17062.x.

32. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1–pl1. doi:10.1126/scisignal.2004088.

33. Engler JR, Robinson AE, Smirnov I, Hodgson JD, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ, Jones C. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012;7(8):e43339. doi:10.1371/journal.pone.0043339.

34. Wogram E, Wendt S, Matyash M, Pivneva T, Draguhn A, Kettenmann H. The “Big-Bang” for modern glial biology: translation and comments on Pio del Rio-Hortega 1919 series of papers on microglia. Glia. 2016;64(11):1801–1840. doi:10.1002/glia.23046.

35. Nakanata T, Ito J. Bone marrow-derived cells expressing Iba1 are constitutively present as resident tissue macrophages in the mouse cochlea. J Neurosci Res. 2008;86(8):1758–1767. doi:10.1002/jnr.21625.

36. Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Kristensen BW. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as killer (NK) cells and CD3 gamma, delta, epsilon complexes in glioblastoma. Stem Cells Dev. 2010;19(3):415–426. doi:10.1089/scd.2010.0281.
predictors of clinical outcome in glioma. Br J Cancer. 2014;110 (10):2560–2568. doi:10.1038/bjc.2014.162.

49. D’Acquisto F, Crompton T. CD3+CD4−CD8− (double negative) T cells: savours or villains of the immune response? Biochem Pharmacol. 2011;82(4):333–340. doi:10.1016/j.bcp.2011.05.019.

50. Waziri A, Killory B, Ogden AT 3rd, Canoll P, Anderson RCE, Kent SC, Anderson DE, Bruce JN. Preferential in situ CD4+CD56 + T cell activation and expansion within human glioblastoma. J Immunol (Baltimore, Md: 1950). 2008;180(11):7673–7680. doi:10.4049/jimmunol.180.11.7673.

51. Muller A, Brandenburg S, Turkowski K, Muller S, Vajkoczy P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int J Cancer. 2015;137 (2):278–288. doi:10.1002/ijc.29379.

52. Chen Z, Feng X, Herting CJ, Alvarez Garcia V, Nie K, Pong WW, Rasmussen R, Dwiwedi B, Seby S, Wolf SA, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 2017;77:2266–2278. doi:10.1158/0008-5472.CAN-16-2310.

53. Muller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Chen Z, Feng X, Herting CJ, Alvarez Garcia V, Nie K, Pong WW, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2018;19(1):234. doi:10.1186/s13059-017-1362-4.

54. Kmieciak J, Poli A, Bruns NHC, Waha A, Eide GE, Enge P, Zimmer J, Chekenya M. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1–2):71–83. doi:10.1016/j.jneuroim.2013.08.013.

55. Thomas AA, Fisher JL, Rahmei GJ, Hampton TH, Baron U, Olek S, Schwachula T, Rhodes CH, Gui J, Tafe LJ, et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro-oncology. 2015;17(6):801–809. doi:10.1093/neuonc/nou363.

56. Yue Q, Zhang X, Ye H-X, Wang Y, Du Z-G, Yao Y, Mao Y. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol. 2014;116(2):251–259. doi:10.1007/s10665-013-1314-0.

57. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiroaka N, Fuller GN. Incidence and prognostic impact of Foxp3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14 (16):5166–5172. doi:10.1158/1078-0432.CCR-08-0320.

58. Jacobs JFM, Idema AJ, Bol KD, Grote M, van der Vlies IJ, Wesseling P, Adam GJ. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 2010;225(1–2):195–199. doi:10.1016/j.neuroim.2010.05.020.

59. Miyara M, Yoshioka Y, Kito H, Shima T, Wing K, Niwa A, Pariotz C, Tallin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor. Immunity. 2009;30 (6):899–911. doi:10.1016/j.immuni.2009.03.019.

60. Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrfy B, Brastianos PK, Binder DC, Somasjan A, et al. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin Cancer Res. 2017;23 (21):6650–6660. doi:10.1158/1078-0432.CCR-17-0120.

61. Plattner M, Wick W. Tregs in gliomas - the jury is still out. Neuro-oncology. 2015;17(6):769–770. doi:10.1093/neuonc/nov034.

62. Vadasz Z, Toubi E. FoxP3 expression in macrophages, cancer, and B-cells-is it real? Clin Rev Allergy Immunol. 2017;52(3):364–372. doi:10.1007/s12016-016-8572-5.

63. Nooshmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pellsoki CE, Sulman EP, Bhat KP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522. doi:10.1016/j.ccr.2010.03.017.

64. Amankulor NM, Kim Y, Arora S, Kargl J, Sulzweg F, Hanke M, Margineantu DH, Rao A, Bolouri H, Delrow J, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31(8):774–786. doi:10.1101/gad.294991.116.

65. Wang Q, Hu B, Hu X, Kim H, Squarrito M, Scarpice L, deCarvalho AC, Lyu S, Li P, Li Y, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2018;33 (1):152. doi:10.1016/j.ccell.2017.12.012.

66. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.

67. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2089. doi:10.1056/NEJMoa1810005.

68. Heiland DH, Haakker G, Delev D, Mercas B, Masahla W, Heynckes S, Gabelein A, Pfeifer D, Carro MS, Weyerbrock A, et al. Heilman comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017;8(26):42214–42225. doi:10.18632/oncotarget.15031.

69. Ndoum EK, Wei J, Taghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncology. 2016;18(2):195–205. doi:10.1093/neuonc/nov172.

70. Berghoff AS, Kiesel B, Waidhalm G, Rajky O, Ricken G, Wöhrer A, et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017;8(26):42214–42225. doi:10.18632/oncotarget.15031.

71. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4(2):124–135. doi:10.1158/2326-6066.CIR-15-0151.

72. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevic J, Durham N, Meyer C, Harris TJ, Albesiano E, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–349. doi:10.1016/j.ijrobp.2012.12.025.

73. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Byllesby KA, Sanders CM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25 (3):477–486. doi:10.1038/s41591-018-0337-7.

74. Lim M, Xia Y, Bettegouda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15 (7):422–426. doi:10.1038/s41571-018-0003-5.